Trial Profile

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amisulpride (Primary) ; Aripiprazole (Primary) ; Olanzapine
Indications Schizophrenia
Focus Therapeutic Use
Acronyms PECANS

Most Recent Events

25 May 2016 Status changed from active, no longer recruiting to completed.
19 Dec 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
12 Jul 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com